Optimization of the Fine Particle Fraction of a Lyophilized Lysozyme Formulation for Dry Powder Inhalation
A new dry powder inhalation technology creates inhalable particles from a coherent lyophilized bulk at the time of inhalation. The aim of this study was to evaluate several approaches to improve the fine particle fraction (FPF) and to understand underlying mechanisms.
Lysozyme was chosen as model drug. Phenylalanine and valine were added, and the freezing process was varied. Lyophilisate characteristics as well as aerosolization behavior was analyzed.
The addition of the crystalline amino acids rendered a dose independent three-fold increase of the FPF. This is possibly due to enhanced fracture properties of the lyophilisates upon impact of the air stream and reduced particle agglomeration/cohesion caused by a rougher surface. This positive effect was well preserved over 3 months of storage. The structure of the lyophilisate was influenced by the freezing process which in turn affected the aerosolization behavior. Liquid nitrogen and vacuum-induced freezing performed best, doubling the FPF. The special cake morphology with elongated channels enabled easy disintegration. The resulting large porous particles comprise a low density being advantageous for a high FPF.
The variation of the lyophilization process and formulation utilizing excipients enabled an optimization of the FPF of the novel lyophilisate based DPI system.
KEY WORDSdry powder inhalation fine particle fraction freeze-drying freezing process lyophilisate
Andersen Cascade Impactor
active pharmaceutical ingredient
dry powder inhaler
fine particle fraction
scanning electron microscopy
glass transition temperature of the max. freeze concentrated solution
ACKNOWLEDGMENTS AND DISCLOSURES
This research project is supported by Boehringer Ingelheim Pharma GmbH & Co. KG. We thank Holger Holakovsky and Gilbert Wuttke for the possibility to do the high speed camera recordings. We also thank Alexandra Pickel for her analytical contribution to this study.
- 10.Yamashita C, Akagi A, Fukunaga Y. Dry powder inhalation system for transpulmonary administration, United States Patent 7735485 2010.Google Scholar
- 16.Patapoff TW, Overcashier DE. The importance of freezing on lyophilization cycle development. BioPharm Int. 2002;72:16–21.Google Scholar
- 21.United States Pharmacopeia 36 Chapter 601—Physical tests and determinations: aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers, vol. 36. United States Pharmacopoial Convention Inc. 2012.Google Scholar
- 26.Franks F, Auffret T. Freeze-drying of pharmaceuticals and biopharmaceuticals. Cambridge: RSC; 2007.Google Scholar
- 32.Stability Testing of New Drug Substances and Products Q1A(R2), International Confernece on Harmonisation of technical requirements for registration of pharmaceuticals for human use 2003.Google Scholar
- 35.Searles JA. Freezing and annealing phenomena in lyophilization. In: Rey L, May JC, editors. Freeze-drying/lyophilization of pharmaceutical and biological products. New York: Marcel Dekker, Inc.; 2004.Google Scholar
- 36.Hsu CC, Nguyen HM, Yeung DA, Brooks DA, Koe GS, Bewley TA, et al. Surface denaturation at solid-void interface—a possible pathway by which opalescent participates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures. Pharm Res. 1995;12:69–77.PubMedCrossRefGoogle Scholar